Vol.

No.

September 11, 2026Sep 11, 2026

DOWNLOAD THE PDF

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero “We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

Cover Story

Cancer History Project Free

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero

“We seem to have a risk of exposure that needed that extra boost of the cigarette to cause the cancer.”

By Sara Willa Ernst

Twenty-five years ago, the attack on the World Trade Center engulfed Ground Zero in a shroud of smoke, leaving Lower Manhattan covered in toxic dust for months.

Clinical

mRNA vaccine for melanoma is hailed as a turning point in medicine
The data from Moderna and Merck’s trial have yet to be presented

By Claire Marie Porter

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida

By Paul Goldberg

Russian general tied to bombing Kyiv children’s hospital shot in apparent retribution hit

By Paul Goldberg

UK Markey’s Tim Mullett: How the Markey Affiliate Network brings NCI-level cancer care to every corner of Kentucky

By University of Kentucky Markey Cancer Center

Cancer Policy

Heidi Overton selected as FDA commissioner; Jared Seehafer named inaugural Deputy Commissioner for Technology and AI

FDA authorizes second e-cigarette with age-gating features

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

In Brief

Samuel Kaffenberger named deputy director for cancer clinical services at U-M Rogel Cancer Center

Dartmouth reconfigures top-tier leadership: Vahdat gets enhanced deputy director role, Dragnev becomes chief of heme onc section, deputy director of clinical affairs

Adam Bacik named CEO of planned MUSC cancer hospital

Rogel Cancer Center founder Max Wicha to retire after 46 years

Raghu Kalluri joins UTMB as cancer center leader, chief scientific officer

Amir Iravani joins UCLA Health to lead Theranostics Program

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Lawrence Fong appointed senior vice president and director of the Fred Hutch Translational Science and Therapeutics Division

Weizhou Zhang named co-leader of expanded immuno-oncology and microenvironment research program at UF Health Cancer Institute

Ramon Sun named co-leader of Mechanisms of Oncogenesis research program at UF Health

UCLA’s Mina Sedrak receives $3.6M NIH grant to improve recovery and reduce accelerated aging after stem cell transplant

PICI invests over $1M in five early career cancer immunotherapy researchers

MD Anderson names 2026 Andrew Sabin Family Fellows

Brown to launch partnership to accelerate cancer research with $37M Starr Foundation investment

Amherst researcher Prabhani Atukorale awarded $2.5M for nano-particle based cancer treatment

Moffitt Cancer Center launches radiopharma program to speed research, clinical translation, manufacturing

Michael Milken to receive Cancer Nation’s inaugural March Forward Award

Clinical Roundup

ASTRO updates guideline on radiation therapy for pancreatic cancer

Alcohol-attributable cancer deaths in the U.S. doubled between 1990 and 2023, Sylvester-led study shows

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find

Botensilimab + balstilimab showed no CRC recurrences in resectable colon cancer, phase II NEST trial shows

Blood cancer patients may have broader stem cell donor options than previously thought, ACCESS trial shows

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

New framework developed for treating liver cancer by UT Southwestern-led research could lead to updated standards

Drugs & Targets

FDA grants accelerated approval to iberdomide combination for MM

FDA grants accelerated approval to camizestrant combination for HR+ metastatic breast cancer

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

EC approves Trodelvy + Keytruda for PD-L1 positive first-line metastatic TNBC

NCI Trials

NCI Trials for September 2026

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

CURRENT ISSUE

Recent Issues

Volume 52 | Issue 33 - September 11, 2026